Endogenex has completed enrollment in the ReCET Clinical Study, a pivotal evaluation of the Endogenex System in adults with type 2 diabetes whose blood glucose levels remain inadequately controlled on non-insulin glucose-lowering medications. The study has enrolled 350 patients across approximately 40 sites in the United States and Australia, moving the clinical-stage medical device developer
FDA backing boosts AVIM therapy momentum. Discover how Orchestra BioMed Holdings, Inc. is shaping the future of hypertension treatment.
Guardant Health partners with Manulife to launch its Shield MCD blood test in Hong Kong, Singapore and the Philippines. Analysis of what this means for oncology.
Bioretec Ltd, the Finland-based medical device developer specializing in fully biodegradable orthopedic implants, has received Breakthrough Device Designation from the U.S. Food and Drug Administration for its RemeOs DrillPin. The designation applies to the use of the biodegradable magnesium-alloy device in pediatric and adult bone fixation procedures, including epimetaphyseal fractures in children over two years